Press release
Systemic Scleroderma Market on Track for Major Expansion by 2032, According to DelveInsight | Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharma, Kadmon Corporation, Gesynta Pharma
DelveInsight's "Systemic Scleroderma Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Systemic Scleroderma, historical and forecasted epidemiology as well as the Systemic Scleroderma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Systemic Scleroderma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Systemic Scleroderma Market Forecast [https://www.delveinsight.com/sample-request/systemic-scleroderma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Systemic Scleroderma Market Report:
*
The Systemic Scleroderma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
*
The incidence and prevalence estimates of SSc in the United States were 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively, according to a study by Fan et al. (2020)
*
According to Coi et al.'s analysis of the literature from 2021, the prevalence of SSc was found to be 22.2 per 100,000 people in Tuscany (Italy), with cases younger than 65 years old having the highest frequency (33.2 per 100,000, CI 95% 29.6-37.3)
*
Key Systemic Scleroderma Companies: Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharmaceuticals, Kadmon Corporation, Gesynta Pharma, Cumberland Pharmaceuticals, Certa Therapeutics, Castle Creek Biosciences, Mitsubishi Tanabe Pharma, Biocad, Prism Pharma Co., Ltd., Boehringer Ingelheim, Janssen Pharmaceutical K.K., GlaxoSmithKline, Bayer, Maruho Co., Ltd., Gesynta Pharma AB, Sanofi, and others
*
Key Systemic Scleroderma Therapies: Brodalumab, MT-0551, EHP-101, KD025/Belumosudil, GS-248, Vasculan, FT011, FCX-013, MT-7117, Divozilimab, C-82, BI 685509, Guselkumab, GSK2330811, Riociguat (Adempas, BAY63-2521), nemolizumab, GS-248, SAR156597, and others
*
The Systemic Scleroderma epidemiology based on gender analyzed that the female population is more prone to Systemic Scleroderma (SSc) as compared to the male population
*
The Systemic Scleroderma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Systemic Scleroderma pipeline products will significantly revolutionize the Systemic Scleroderma market dynamics.
Systemic Scleroderma Overview
Systemic scleroderma, also known as systemic sclerosis (SSc), is a chronic autoimmune disease characterized by excessive collagen deposition and fibrosis (hardening and thickening of tissues) in various organs and tissues throughout the body. It is one of the subtypes of scleroderma, a group of connective tissue disorders that affect the skin, blood vessels, and internal organs.
Get a Free sample for the Systemic Scleroderma Market Report:
https://www.delveinsight.com/report-store/systemic-scleroderma-market [https://www.delveinsight.com/report-store/systemic-scleroderma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Systemic Scleroderma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Systemic Scleroderma Epidemiology Segmentation:
The Systemic Scleroderma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
*
Total Prevalence of Systemic Scleroderma
*
Prevalent Cases of Systemic Scleroderma by severity
*
Gender-specific Prevalence of Systemic Scleroderma
*
Diagnosed Cases of Episodic and Chronic Systemic Scleroderma
Download the report to understand which factors are driving Systemic Scleroderma epidemiology trends @ Systemic Scleroderma Epidemiology Forecast [https://www.delveinsight.com/sample-request/systemic-scleroderma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Systemic Scleroderma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Scleroderma market or expected to get launched during the study period. The analysis covers Systemic Scleroderma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Systemic Scleroderma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Systemic Scleroderma Therapies and Key Companies
*
Brodalumab: Kyowa Hakko Kirin
*
MT-0551: Mitsubishi Tanabe Pharma Corporation
*
EHP-101: Emerald Health Pharmaceuticals
*
KD025/Belumosudil: Kadmon Corporation
*
GS-248: Gesynta Pharma
*
Vasculan: Cumberland Pharmaceuticals
*
FT011: Certa Therapeutics
*
FCX-013: Castle Creek Biosciences
*
MT-7117: Mitsubishi Tanabe Pharma
*
Divozilimab: Biocad
*
C-82: Prism Pharma Co., Ltd.
*
BI 685509: Boehringer Ingelheim
*
Guselkumab: Janssen Pharmaceutical K.K.
*
GSK2330811: GlaxoSmithKline
*
Riociguat (Adempas, BAY63-2521): Bayer
*
nemolizumab: Maruho Co., Ltd.
*
GS-248: Gesynta Pharma AB
*
SAR156597: Sanofi
Discover more about therapies set to grab major Systemic Scleroderma market share @ Systemic Scleroderma Treatment Market [https://www.delveinsight.com/sample-request/systemic-scleroderma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Systemic Scleroderma Market Strengths
*
Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Fabry disease.
*
Newborn screening for Fabry disease has been implemented in several countries, enabling the early detection of individuals with Fabry mutations.
*
Many therapies are under investigation in various phases of clinical trials. These include pegylated forms of -GAL, gene therapy, and substrate reduction therapy.
Systemic Scleroderma Market Opportunities
*
Challenges in diagnoses
*
Development of novel therapies
*
Limitations in gene therapy
*
Poor disease understanding
*
Clinical biomarkers
Scope of the Systemic Scleroderma Market Report
*
Study Period: 2019-2032
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Systemic Scleroderma Companies: Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharmaceuticals, Kadmon Corporation, Gesynta Pharma, Cumberland Pharmaceuticals, Certa Therapeutics, Castle Creek Biosciences, Mitsubishi Tanabe Pharma, Biocad, Prism Pharma Co., Ltd., Boehringer Ingelheim, Janssen Pharmaceutical K.K., GlaxoSmithKline, Bayer, Maruho Co., Ltd., Gesynta Pharma AB, Sanofi, and others
*
Key Systemic Scleroderma Therapies: Brodalumab, MT-0551, EHP-101, KD025/Belumosudil, GS-248, Vasculan, FT011, FCX-013, MT-7117, Divozilimab, C-82, BI 685509, Guselkumab, GSK2330811, Riociguat (Adempas, BAY63-2521), nemolizumab, GS-248, SAR156597, and others
*
Systemic Scleroderma Therapeutic Assessment: Systemic Scleroderma current marketed and Systemic Scleroderma emerging therapies
*
Systemic Scleroderma Market Dynamics: Systemic Scleroderma market drivers and Systemic Scleroderma market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Systemic Scleroderma Unmet Needs, KOL's views, Analyst's views, Systemic Scleroderma Market Access and Reimbursement
To know more about Systemic Scleroderma companies working in the treatment market, visit @ Systemic Scleroderma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/systemic-scleroderma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Systemic Scleroderma Market Report Introduction
2. Executive Summary for Systemic Scleroderma
3. SWOT analysis of Systemic Scleroderma
4. Systemic Scleroderma Patient Share (%) Overview at a Glance
5. Systemic Scleroderma Market Overview at a Glance
6. Systemic Scleroderma Disease Background and Overview
7. Systemic Scleroderma Epidemiology and Patient Population
8. Country-Specific Patient Population of Systemic Scleroderma
9. Systemic Scleroderma Current Treatment and Medical Practices
10. Systemic Scleroderma Unmet Needs
11. Systemic Scleroderma Emerging Therapies
12. Systemic Scleroderma Market Outlook
13. Country-Wise Systemic Scleroderma Market Analysis (2019-2032)
14. Systemic Scleroderma Market Access and Reimbursement of Therapies
15. Systemic Scleroderma Market Drivers
16. Systemic Scleroderma Market Barriers
17. Systemic Scleroderma Appendix
18. Systemic Scleroderma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=systemic-scleroderma-market-on-track-for-major-expansion-by-2032-according-to-delveinsight-kyowa-hakko-kirin-mitsubishi-tanabe-pharma-emerald-health-pharma-kadmon-corporation-gesynta-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Systemic Scleroderma Market on Track for Major Expansion by 2032, According to DelveInsight | Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharma, Kadmon Corporation, Gesynta Pharma here
News-ID: 4119000 • Views: …
More Releases from ABNewswire
Exploring the Impact of U.S. Government Shutdown on the Global Markets - An Excl …
Image: https://www.abnewswire.com/upload/2025/11/6ab92174e3dc0ee6c1bfafc8e655cfb4.jpg
A shutdown of the U.S. federal government, when Congress fails to pass spending legislation and many agencies cease non-essential operations, poses a material risk to the economy. But when viewed through the lens of market history and global asset flows, the evidence suggests that such shutdowns are often absorbed by the markets and, in several ways, may present tactical opportunities for globally diversified investors.
1. What a U.S. Government Shutdown…
Green Ammonia Market size growing at CAGR of 82.47% by 2030 | Rising Fertilizer …
The latest research by Mordor Intelligence covers the "Green Ammonia Market," delivering insights into market dynamics, drivers of growth, and long-term forecasts.
Green Ammonia Market Overview:
The global green ammonia market is expanding steadily as countries accelerate the shift toward low-carbon fertilizer, marine fuel, power generation, and hydrogen transport solutions. The green ammonia market [https://www.mordorintelligence.com/industry-reports/green-ammonia-market?utm_source=abnewswire] size is expected to grow from 0.27 million tons in 2025 to 5.41 million tons by 2030,…
Point of Care Diagnostics Market to Reach USD 84.93 Billion by 2030, Driven by R …
Mordor Intelligence has published a new report on Point Of Care Diagnostics Market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
The Point Of Care Diagnostics Market [https://www.mordorintelligence.com/industry-reports/point-of-care-diagnostics?utm_source=abnewswire] size is estimated at USD 53.63 billion in 2025, and is expected to reach USD 84.93 billion by 2030, at a CAGR of 9.63% during the forecast period (2025-2030). The market's growth is fueled by the increasing need for rapid,…
Enteral Feeding Devices Market Forecast to Reach USD 4.94 Billion by 2030, Drive …
Mordor Intelligence has published a new report on enteral feeding devices market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
The enteral feeding devices market [https://www.mordorintelligence.com/industry-reports/enteral-feeding-devices-market?utm_source=abnewswire] is projected to grow from approximately USD 3.72 billion in 2025 to USD 4.94 billion by 2030, according to a recent report by Mordor Intelligence. The growth reflects a compound annual growth rate (CAGR) of around 5.84 percent, driven primarily by technological…
More Releases for Systemic
What Is Driving Global Systemic Aspergillosis And Systemic Candidiasis Market Gr …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Systemic Aspergillosis And Systemic Candidiasis Market Size Growth Forecast: What to Expect by 2025?
The market valuation for systemic aspergillosis and systemic candidiasis has experienced consistent upward momentum across recent years, projected to advance from a figure of $7.24 billion in 2024 to reach $7.57 billion by 2025, reflecting…
Transformative Trends Impacting the Systemic Aspergillosis And Systemic Candidia …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Systemic Aspergillosis And Systemic Candidiasis Market Size By 2025?
The growth trend of the systemic aspergillosis and systemic candidiasis market has been steadily ascending in the past few years. The market size will inflate from $7.24 billion in 2024 to $7.59 billion in 2025, indicating…
Systemic Aspergillosis And Systemic Candidasis Market Size by Type, Application, …
According to Market Research Intellect, the global Systemic Aspergillosis And Systemic Candidasis market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The growing prevalence of invasive fungal infections, especially in immunocompromised persons, is propelling the global…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market - Industry Over …
The systemic aspergillosis and systemic candidiasis treatment market is gaining significant attention within the global healthcare and pharmaceutical industries due to the increasing incidence of life-threatening fungal infections among immunocompromised individuals. Both systemic aspergillosis and systemic candidiasis are opportunistic fungal infections, often affecting patients with weakened immune systems due to cancer therapy, organ transplantation, HIV/AIDS, or intensive care treatments.
The systemic aspergillosis and systemic candidiasis treatment market was valued at approximately…
Systemic Aspergillosis and Systemic Candidiasis Market Share, Sales Channels and …
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
The systemic aspergillos is and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019. The market is estimated to grow at a CAGR of 4.0% from 2020 to 2027.
To get sample Copy of the report, along with…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market Insight & Futur …
(Portland, United States): Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Systemic Aspergillosis and Systemic Candidiasis Treatment Market in the latest research report added by Big Market Research. The recent research report on the global Systemic Aspergillosis and Systemic Candidiasis Treatment Market presents the latest industry data and future trends, allowing you to recognize the products and end…
